首页> 美国卫生研究院文献>Genetics >Haploidy Diploidy and Evolution of Antifungal Drug Resistance in Saccharomyces cerevisiae
【2h】

Haploidy Diploidy and Evolution of Antifungal Drug Resistance in Saccharomyces cerevisiae

机译:酿酒酵母的单倍体二倍体及其抗真菌药性的演变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We tested the hypothesis that the time course of the evolution of antifungal drug resistance depends on the ploidy of the fungus. The experiments were designed to measure the initial response to the selection imposed by the antifungal drug fluconazole up to and including the fixation of the first resistance mutation in populations of Saccharomyces cerevisiae. Under conditions of low drug concentration, mutations in the genes PDR1 and PDR3, which regulate the ABC transporters implicated in resistance to fluconazole, are favored. In this environment, diploid populations of defined size consistently became fixed for a resistance mutation sooner than haploid populations. Experiments manipulating population sizes showed that this advantage of diploids was due to increased mutation availability relative to that of haploids; in effect, diploids have twice the number of mutational targets as haploids and hence have a reduced waiting time for mutations to occur. Under conditions of high drug concentration, recessive mutations in ERG3, which result in resistance through altered sterol synthesis, are favored. In this environment, haploids consistently achieved resistance much sooner than diploids. When 29 haploid and 29 diploid populations were evolved for 100 generations in low drug concentration, the mutations fixed in diploid populations were all dominant, while the mutations fixed in haploid populations were either recessive (16 populations) or dominant (13 populations). Further, the spectrum of the 53 nonsynonymous mutations identified at the sequence level was different between haploids and diploids. These results fit existing theory on the relative abilities of haploids and diploids to adapt and suggest that the ploidy of the fungal pathogen has a strong impact on the evolution of fluconazole resistance.
机译:我们检验了以下假设:抗真菌药物耐药性演变的时间过程取决于真菌的倍性。设计实验是为了测量对抗真菌药氟康唑的选择的初始反应,直至并包括酿酒酵母种群中第一个耐药突变的固定。在低药物浓度的条件下,优选基因PDR1和PDR3的突变,这些基因调节与氟康唑耐药有关的ABC转运蛋白。在这种环境下,确定大小的二倍体种群始终比单倍体种群更早地因抗性突变而变得固定。操纵种群大小的实验表明,二倍体的这种优势是由于相对于单倍体而言,突变的可获得性增加了。实际上,二倍体的突变靶标数量是单倍体的两倍,因此减少了等待突变发生的时间。在高药物浓度的条件下,ERG3的隐性突变会通过固醇合成的改变而产生耐药性,因此受到人们的青睐。在这种环境下,单倍体始终比二倍体早获得抗药性。当在低药物浓度下进化29个单倍体和29个二倍体种群100代时,固定在二倍体种群中的突变都是显性的,而固定在单倍体种群中的突变是隐性的(16个种群)或显性的(13个种群)。此外,在单倍体和二倍体之间在序列水平鉴定的53个非同义突变的光谱是不同的。这些结果符合有关单倍体和二倍体相对适应能力的现有理论,并表明真菌病原体的倍性对氟康唑耐药性的演变有很大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号